AIDS Medicine for Poor Countries
|
Posted by Daniel Workman Sep 6, 2006 |
Don't miss our article on how anti-HIV drugs have been elevated to a special status in international trade, thanks to the initiatives of the Clinton Foundation and such commercial entities as Gilead and Bristol-Myers Squibb.
Gilead Sciences aims to improve accessibility to AIDS drugs in underprivileged nations by:
- offering anti-HIV medications at no-profit prices;
- providing its medications for clinical studies designed to help determine the best treatment strategies for resource-limited settings; and
- dedicating Gilead staff to support and mentor through treatment programs based on Gilead medicines like Truvada.
The 97 countries that benefit from the Gilead Access Program are:
Afghanistan, Algeria, Angola, Antigua and Barbuda
Bahamas, Bangladesh, Barbados, Belize, Benin, Bhutan, Bolivia, Botswana, Burkina Faso, Burundi
Cambodia, Cameroon, Cape Verde, Central African Republic, Chad, Comoros, Côte d'Ivoire
Democratic Republic of Congo, Djibouti, Dominica, Dominican Republic
Egypt, Equatorial Guinea, Eritrea, Ethiopia
Gabon, Gambia, Ghana, Grenada, Guatemala, Guinea, Guinea Bissau, Guyana
Haiti, Honduras
Indonesia, Jamaica
Kenya, Kiribati, Kyrgyzstan
Laos, Lesotho, Liberia, Libya
Madagascar, Malawi, Maldives, Mali, Mauritania, Mauritius, Moldova, Mongolia, Morocco, Mozambique, Myanmar
Namibia, Nepal, Nicaragua, Niger, Nigeria
Pakistan, Papua New Guinea
Republic of Congo, Rwanda
St. Kitts and Nevis, St. Lucia, St. Vincent and the Grenadines, Samoa, São Tomé and Príncipe, Senegal, Seychelles, Sierra Leone, Solomon Islands, Somalia, South Africa, Sudan, Suriname, Swaziland, Syria
Tajikistan, Tanzania, Timor-Leste, Togo, Trinidad and Tobago, Tunisia, Tuvalu
Uganda, Uzbekistan
Vanuatu, Vietnam
Yemen, Zambia, Zimbabwe
Source: Gilead Access Program